CD28 and cancer: The observed increase in mutation load in the low-risk group, alongside the elevated expression of immune checkpoint markers such as CD24, CD28, CTLA-4, and TIGIT in the high-risk group, underscores the complex interplay between genetic mutations and immune escape mechanisms in cancer development.